Dollar rebounds despite Fed independence worries; euro slips
FORT WORTH - On Thursday, Omnicell , Inc. (NASDAQ:OMCL) reported second quarter earnings and revenue that surpassed analyst expectations, driven by strong demand for its point-of-care connected devices.
The pharmacy automation company’s shares gained 2.76% in pre-market trading after the release.
The company posted adjusted earnings of $0.45 per share for the second quarter, significantly beating the analyst consensus of $0.27. Revenue reached $290.56 million, exceeding expectations of $275.28 million and representing a 5% increase from the same quarter last year.
"We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided guidance," said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.
The company highlighted notable strength in its point-of-care connected devices, including its XT Series automated dispensing cabinets and the XTExtend console. Technical services, SaaS and Expert Services, and consumables revenues also contributed to the positive results.
For the third quarter, Omnicell forecasts revenue between $290 million and $300 million, above the consensus estimate of $284.1 million, and adjusted earnings per share of $0.30 to $0.37, compared to analysts’ expectations of $0.37.
The company also raised its full-year 2025 guidance, now projecting revenue of $1.13 billion to $1.16 billion and adjusted earnings per share of $1.40 to $1.65, compared to the analyst consensus of $1.37.
Omnicell reported GAAP net income of $6 million, or $0.12 per diluted share, up from $4 million, or $0.08 per share, in the second quarter of 2024. The company ended the quarter with $399 million in cash and cash equivalents and total debt of $342 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.